Tag: radioligand therapy market share

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Radioligand Therapy Industry Expected To Reach By 2029, Starting From 2025 Levels?

The radioligand therapy market size has shown rapid expansion in recent years. It is anticipated to grow from $6.01 billion in 2024 to $6.64 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.5%. The historical growth of this market can be attributed to factors such as the rise in liquid biopsy usage, the emergence of tumor-agnostic therapies, the integration of artificial intelligence in oncology, the expanding pipeline of bispecific antibodies, and an increase in government funding for cancer research.

The radioligand therapy market size is anticipated to undergo substantial expansion over the upcoming years. Its value is projected to reach $9.77 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.2%. This expected increase during the forecast period is driven by factors such as increasing investments from major pharmaceutical companies in oncology startups, a broader application of real-world evidence, advancements in radiopharmaceutical and theranostics research, burgeoning collaborations between academia and industry, and a rise in the occurrence of rare and orphan cancers. Prominent trends for the forecast period include AI-powered radiopharmaceutical design, theranostics employing dual imaging-therapy platforms, microfluidics-based radiotracer synthesis, next-generation alpha-emitting isotopes, and personalized 3D-printed dosimetry devices.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

Which Factors And Drivers Are Influencing The Radioligand Therapy Market In 2025?

The projected rise in cancer cases is anticipated to drive expansion within the radioligand therapy market. Cancer is characterized by the unregulated proliferation of aberrant cells, which can infiltrate adjacent tissues and disseminate throughout the body. The increasing occurrence of cancer is linked to prolonged exposure to environmental contaminants, which harm DNA, interfere with cellular processes, and foster irregular cell development. Radioligand therapy addresses cancer by targeting radiation directly at tumor cells via ligands that attach to specific receptors, thereby reducing damage to healthy tissues while internally eradicating malignant cells. For instance, in January 2022, according to the American Cancer Society, a US-based cancer awareness non-profit organization, the US was projected to see an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths, reaching up to approximately 1,670 deaths on daily basis. Consequently, the growing rate of cancer diagnoses is stimulating the expansion of the radioligand therapy market.

What Are The Leading Segments Analyzed In The Radioligand Therapy Market?

The radioligand therapy market covered in this report is segmented

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

Which Trends Are Impacting The Radioligand Therapy Market?

Leading companies in the radioligand therapy market are prioritizing the development of advanced solutions, including radioligand therapy facilities, to improve production efficiency and maintain consistent quality and safety measures during the manufacturing and distribution of targeted cancer treatments. These specialized centers are specifically designed to manage and deliver radioactive drugs for targeted cancer treatment, utilizing advanced imaging systems and radiation shielding, while ensuring safety through trained staff and strict operational protocols. For example, in January 2024, Novartis AG, a pharmaceutical company based in Switzerland, announced the automation of its new large-scale radioligand therapy (RLT) production facility in Indiana. This plant secured Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility stands as Novartis’s largest and most advanced site dedicated to RLT, built for efficient, time-sensitive production, and features plans for fully automated production lines, enabling substantial increases in supply to address growing patient demand in the US and Canada.

Which Major Firms Are Strengthening Their Position In The Radioligand Therapy Industry?

Major companies operating in the radioligand therapy market are Bayer AG, Novartis AG, Eli Lilly and Company, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Molecular Partners AG, Telix Pharmaceuticals, Nanobiotix S.A., Mariana Oncology Inc., Artios Pharma Limited, AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C‑Ray Therapeutics Inc., OncoSil Medical Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Radioligand Therapy Market?

North America was the largest region in the radioligand therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Radioligand Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27403&type=smp

Browse Through More Reports Similar to the Global Radioligand Therapy Market 2025, By The Business Research Company

Property Management Service Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report

Real Estate Rental Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/real-estate-rental-global-market-report

Financial Accounting Advisory Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/financial-accounting-advisory-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Radioligand Therapy Market Evolve in Terms of Growth and Size by 2029?

The market size of radioligand therapy has seen significant growth recently and is anticipated to rise from $6.01 billion in 2024 to $6.64 billion in 2025, accounting for a compound annual growth rate (CAGR) of 10.5%. Several factors contributed to this growth during the historic period, including an upsurge in liquid biopsy usage, the advent of tumor-agnostic therapies, application of artificial intelligence in oncology, the expanding pipeline of bispecific antibodies, and amplified government funding towards cancer.

Over the coming years, the radioligand therapy market is set to experience considerable expansion, with projections indicating growth to a value of $9.77 billion by 2029, reflecting a compound annual growth rate (CAGR) of 10.2%. This growth over the forecast period is likely to be influenced by factors such as increased financial backing from large pharmaceutical companies in oncology startups, a growing reliance on real-world evidentiary data, developments in radiopharmaceutical and theranostics studies, expanded collaborations between the academic and industrial sectors, and an uptick in the occurrence of rare and orphan cancers. Expected trends over the forecast period encompass advancements in AI-mediated radiopharmaceutical design, dual imaging-therapy platforms in theranostics, the synthesis of microfluidics-based radiotracers, the emergence of next-generation alpha-emitting isotopes, and the creation of 3D-printed personalized dosimetry devices.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

What factors are expected to fuel Radioligand Therapy market growth in the coming years?

The rise in cancer incidence is anticipated to boost the radioligand therapy market’s expansion. Characterized by the uncontrolled multiplication of abnormal cells that can infiltrate nearby tissues and metastasize throughout the body, cancer is becoming more common due to the prolonged exposure to environmental pollutants. These pollutants harm DNA, disrupt cellular function, and encourage anomalous cell proliferation. Radioligand therapy takes on the task of treating cancer by using ligands to guide radiation to tumorous cells. This method minimizes damage to healthy tissue and destroys cancer cells from within. As reported by the American Cancer Society, a prominent cancer awareness charity in the US, in January 2022, the country anticipates around 1.9 million new cancer diagnoses and approximately 609,360 cancer-linked fatalities, resulting in an estimate of 1,670 deaths each day. Therefore, the escalating incidence of cancer propels the growth of the radioligand therapy market.

What Are The Key Findings From The Segmentation Analysis Of The Radioligand Therapy Market?

The radioligand therapy market covered in this report is segmented

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

Which Trends Are Expected To Shape The Future Of The Radioligand Therapy Market?

Leading organizations in the radioligand therapy market are concentrating on creating innovative solutions like radioligand therapy facilities to boost production efficiency and enforce consistent quality and safety norms in the production and distribution of targeted cancer therapies. These facilities are specialized centers equipped to manage and dispense radioactive drugs for targeted cancer treatments, utilizing state-of-the-art imaging systems and radiation shield, all while maintaining safety through well-trained staff and rigorous procedures. In January 2024, Novartis AG, a pharmaceutical firm based in Switzerland, disclosed the automation of its new high-capacity radioligand therapy (RLT) manufacturing plant in Indiana, which has been approved by the Food and Drug Administration (FDA) for commercial production. Spanning 70,000 square feet, this facility is the biggest and most sophisticated Novartis site committed to RLT. It’s designed for efficient, timely production and incorporates plans for fully automated production lines, facilitating significant supply expansions to cater to the increasing patient demand in the US and Canada.

What Are The Most Active Companies In The Radioligand Therapy Market Today?

Major companies operating in the radioligand therapy market are Bayer AG, Novartis AG, Eli Lilly and Company, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Molecular Partners AG, Telix Pharmaceuticals, Nanobiotix S.A., Mariana Oncology Inc., Artios Pharma Limited, AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc., OncoSil Medical Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Which Regional Markets Are Attracting The Most Investment In Radioligand Therapy?

North America was the largest region in the radioligand therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=27403&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model